Adapt Pharma announced that it has received FDA approval for a 2 mg dose version of Narcan naloxone nasal spray for the treatment of opioid overdose for opioid-addicted patients who would likely experience severe withdrawal if given the 4 mg dose.
The 4 mg per dose formulation of Narcan was approved by the FDA in November 2015, and Adapt launched the nasal spray in the US in February 2016.
Read the Adapt Pharma press release.
